To assess the oncogene properties of superenhancer‐related FASRL, we selected several lncRNAs that were proven to promote HCC progression, including lncRNA PCNAP1,[17] lncTCF7,[18] TUG1,[19] HULC,[20] GIHCG,[21] and LINC00662,[22] to compare the effect of those lncRNAs with that of FASRL on cell proliferation in HCC cell lines. The gene discussed is TUG1; the disease is hepatocellular carcinoma.